(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 July 2012 (19.07.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/096985 A1

(51) **International Patent Classification**:
A61K 31/167 (2006.01) *A61K 9/00* (2006.01)
A61P 13/00 (2006.01) *A61K 9/20* (2006.01)
A61P 13/10 (2006.01)

(21) **International Application Number**:
PCT/US2012/020813

(22) **International Filing Date**:
10 January 2012 (10.01.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/431,334 10 January 2011 (10.01.2011) US
61/551,923 26 October 2011 (26.10.2011) US

(71) **Applicant** *(for all designated States except US)*: **TARIS BIOMEDICAL, INC.** [US/US]; 99 Hayden Avenue, Suite 100, Lexington, MA 02421 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **HIMES, Julie** [US/US]; 99 Hayden Avenue, Lexington, MA 02421 (US). **GIESING, Dennis** [US/US]; 4421 SW Gull Point Drive, Lee's Summit, MO 64082 (US). **LARRIVEEE-ELKINS, Cheryl** [US/US]; 300 Central Street, Framingham, MA 01701 (US). **CIMA, Michael J.** [US/US]; 184 Mystic Valley Parkway, Winchester, MA 01890 (US). **SARMA, Purnanand** [US/US]; 683 Strawberry Hill Road, Concord, MA 01742 (US). **GOLDENHEIM, Paul** [US/US]; 16 Hillside Avenue, Cambridge, MA 02140 (US).

(74) **Agents**: **KING, Kevin, W.** et al.; Sutherland Asbill & Brennan LLP, 999 Peachtree Street, NE, Atlanta, GA 30309-3996 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2012/096985 A1

(54) **Title**: LIDOCAINE REGIMEN FOR THE USE OF SUSTAINED TREATMENT OF BLADDER PAIN AND IRRITATIVE VOIDING

(57) **Abstract**: Method are provided for treating a patient having bladder pain and/or irritative voiding symptoms. The method includes administering to the patient's bladder lidocaine or another anesthetic agent continuously over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect which is sustained beyond the end of the treatment period.